| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029155993 |
| P356 | DOI | 10.1038/SJ.BJC.6603049 |
| P932 | PMC publication ID | 2361225 |
| P698 | PubMed publication ID | 16552436 |
| P5875 | ResearchGate publication ID | 7227462 |
| P2093 | author name string | R Sharma | |
| P Beale | |||
| L Horvath | |||
| L Rivory | |||
| S J Clarke | |||
| S Ong | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials | Q30913489 | ||
| Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy | Q33345661 | ||
| Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study | Q33366028 | ||
| Where do we stand with 5-fluorouracil? | Q33800905 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer | Q33855276 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Clinical pharmacokinetics of capecitabine | Q34207262 | ||
| Body surface area as a determinant of pharmacokinetics and drug dosing | Q34273673 | ||
| Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 | ||
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 | ||
| Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study | Q34519158 | ||
| Folate status and the safety profile of antifolates | Q34649600 | ||
| Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients | Q35544834 | ||
| Fluorouracil: biochemistry and pharmacology | Q39527807 | ||
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin | Q40580831 | ||
| Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative | Q41123160 | ||
| Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents | Q41260165 | ||
| Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. | Q43590571 | ||
| A new complication of chemotherapy administered via permanent indwelling central venous catheter | Q55064705 | ||
| Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients | Q73154285 | ||
| Warfarin-5-FU interaction--a consecutive case series | Q73277249 | ||
| Colorectal cancer | Q93917269 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| capecitabine | Q420207 | ||
| P304 | page(s) | 964-968 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer | |
| P478 | volume | 94 |
| Q88867253 | Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer |
| Q37303878 | Capecitabine: have we got the dose right? |
| Q36459787 | Clinical pharmacology of cancer therapies in older adults. |
| Q64115864 | Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine |
| Q56391087 | Dose calculation of anticancer drugs |
| Q37050501 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments |
| Q27028095 | Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials |
| Q34206038 | Interpreting Research on Dietary Supplements and Cancer - What is the Take Home Message? |
| Q36498946 | Management of a locally advanced rectal cancer in a patient who declined surgery |
| Q38933901 | On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. |
| Q79463052 | Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers |
| Q36715263 | Pharmacokinetics of chemotherapy in the older patient. |
| Q37340624 | Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash |
| Q37187386 | Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. |
| Q38373831 | Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. |
| Q38085525 | Red cell or serum folate: what to do in clinical practice? |
| Q37781051 | Safety of capecitabine: a review |
| Q33781843 | Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer |
Search more.